Phase 1 Study of PF-08046033 in Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping to treat cancer. The study includes adult participants who have advanced cancers that cannot be removed by surgery or have spread to other parts of the body. These cancers include non-small cell lung cancer, esophageal squamous cell cancer, and melanoma. The study has two parts: In the first part, small groups of participants receive increasing doses of the study medicine. This helps researchers find a dose that is safe and suitable for further testing. Once a suitable dose is identified, the second part enrolls more participants with specific cancer types to better understand the safety of the medicine and whether it shows signs of helping control the cancer. Participants receive the study medicine through regular treatment cycles and are closely monitored for side effects and how their cancer responds. The information from this study will help researchers decide whether PF-08046033 should be studied further in later-stage clinical trials.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznanie raka płuc bez drobnych komórek, raka przełyku lub czerniaków skóry, które się rozprzestrzeniły lub nie można ich usunąć operacyjnie
- •Stan zdrowia na tyle dobry, aby tolerować badanie (skala 0-1)
- •Nowotwór się rozwijał mimo leczenia lub pacjent nie tolerował standardowego leczenia
- •Nowotwór można zmierzyć badaniami obrazowymi lub innymi metodami
✗ Disqualifies
- •Przerzuty do mózgu aktywne i powodujące objawy
- •Neuropatia (uszkodzenie nerwów) w stopniu umiarkowanym lub ciężkim
- •Niekontrolowana cukrzyca
- •Nielechone zakrzepy krwi
- •Wcześniejsze leczenie lekami skierowanymi na GPNMB
- •Uczulenie na składniki leku
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (6)
Presbyterian/St Lukes Medical Center
Denver, United States
Sarah Cannon Research Institute at HealthONE
Denver, United States
Sarah Cannon Research Institute- Pharmacy
Nashville, United States
SCRI Oncology Partners
Nashville, United States
Hospital Oncologico Dr. Isaac Gonzalez-Martinez
Rio Piedras, Puerto Rico
Pan American Center for Oncology Trials, LLC
Rio Piedras, Puerto Rico
Trial contact
Pfizer CT.gov Call Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.